Magnetic Biosensor Could Enable Simultaneous Monitoring of Thousands of Protein-Ligand Bindings

The technology, which is being commercialized by start-up firm MagArray, is aimed primarily at drug screening applications, allowing pharmaceutical firms to test compounds against a wide number of proteins for off-target binding, said one of the researchers.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.